Map Key
Generic Enzyme
Generic kinase
Protein kinase
Lipid kinase
Generic phosphatase
Protein phosphatase
Lipid phosphatase
Generic phospholipase
Generic protease
RAS - superfamily
G beta/gamma
Regulators (GDI, GAP, GEF)
Generic channel
Ligand-gated channel
Voltage-gated channel
Normal process
Pathological process
Positive effect
Negative effect
Unspecified effect
Technical link
Disrupts in disease
Emerges in disease
Enhances in disease
Weakens in disease
Organsim specific interaction

Generic binding protein
Receptor ligand
Cell membrane glycoprotein
Transcription factor
Inorganic ion
Predicted metabolite or user's structure
Generic receptor
Receptors with enzyme activity

Normal process
Pathological process
Covalent modifications
Transcription regulation
MicroRNA binding
Influence on expression
Unspecified interactions
Pharmacological effect
Toxic effect
Group relation
Complex subunit
Similarity reaction
A complex or a group
Organism specific object

Signal transduction cAMP signaling

Log In to Post A Comment

Signal transduction cAMP signaling

cAMP Signaling

Adenylate cyclases ( AC s)  are a family ofenzymes that produce cyclic AMP ( cAMP ) from ATP upon extracellular stimulation.To date, at least 9 membrane-bound AC s have been isolated and characterized.Intracellular signaling via cAMP generates downstream effects that range fromchanges in the function of ion channels to changes in intracellular energy metabolism andgene transcription [1].

Adenylate cyclases are capable of integrating positive and negative signalsthat act directly from G protein-coupled receptors ( GPCR s) through stimulationof the G-protein alpha and beta/gamma subunits or indirectly viaintracellular signaling by protein kinases: Protein kinase A ( PKA ),Calcium/calmodulin-dependent protein kinase ( CaMK ), and Protein kinase C (PKC ).

Stimulation through G-protein alpha-s is the major mechanism, by whichAC s are activated and cAMP levels are elevated. Whereas all isoforms ofAC s are potentially activated by G-protein alpha-s -coupled receptors, theinhibition by G-protein alpha-i family -coupled receptors appears to be isozymespecific. G-protein alpha-i family acts as a noncompetitive inhibitor ofG-protein alpha-s -stimulated Adenylate cyclases 1, 5 and 6 ( Adenylate cyclasetype I, Adenylate cyclase type V and Adenylate cyclase type VI ), anddecreases level of cAMP [2]. G-proteins beta/gamma subunitsstimulate Adenylate cyclases 2, 4 and 7 ( Adenylate cyclase type II, Adenylatecyclase type IV and Adenylate cyclase type VII ) and inhibit Adenylatecyclase type I, Adenylate cyclase type V and Adenylate cyclase typeVI.

Adenylate cyclases type I, II, III, V, VI and VII have been shown to bedirectly phosphorylated by PKC isoenzymes. Adenylate cyclase type V isphosphorylated and activated by Protein kinase C alpha and zeta ( PKC-alpha,PKC-zeta ); Adenylate cyclase type II - by PKC-alpha; Adenylatecyclase type VII - by Protein kinase C delta ( PKC-delta ). Adenylatecyclase type VI is phosphorylated and inhibited by PKC. Adenylate cyclasestype I is phosphorylated and inhibited by Calcium/calmodulin-dependent protein kinaseIV ( CaMK IV ), Adenylate cyclases type III is phosphorylated and inhibitedby Calcium/calmodulin-dependent protein kinase (CaM kinase) II ( CaMK II ).Adenylate cyclases type IX is indirectly inhibited by Ca('2+) via theactivation of Calcineurin [2].

PKA is a significant target of cAMP. PKA consist of Protein kinase,cAMP-dependent, regulatory ( PKA-reg (cAMP-dependent) ) and catalytic ( PKA-cat(cAMP-dependent) ) subunits. PKA-reg (cAMP-dependent bind and inhibit thePKA-cat (cAMP-dependent). cAMP molecules bind to each regulatory subunit,eliciting a reversible conformational change that releases active catalytic subunits[3]. PKA directly phosphorylates and inhibits Adenylate cyclasestype V and IV, realizing feedback regulation.

PKA also phosphorylates and stimulates cAMP responsive element binding protein1 ( CREB1 ) [4], Ryanodine receptor 1 ( RYR1 ) [5], Lipase, hormone-sensitive ( LIPS ) [6], Phosphorylasekinase, alpha ( PHK alpha ), P hospholamban, KDEL (Lys-Asp-Glu-Leu)endoplasmic reticulum protein retention receptors ( KDELR ), and inhibits Glycogensynthase kinase-alpha/beta ( GSK3alpha/beta ) [7].

Other targets for cAMP are guanine nucleotide exchange factors (GEFs) thatmodulate activity of small GTPases. cAMP binding to Rap guanine nucleotideexchange factors (GEF) 3 and 4 ( cAMP-GEFI and cAMP-GEFII ) activate RAP1Aand RAP2A, members of RAS oncogene family ( RAP-1A and RAP-2A) pathways,respectively [8], [9].